Navigation Links
Perrigo Company Confirms Patent Challenge for Clobetasol Propionate Emulsion Foam
Date:7/14/2010

ALLEGAN, Mich., July 14 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Emulsion Foam, 0.05% and notified Stiefel Research Australia Pty. Ltd., the listed patent owner. Perrigo believes it is first-to-file on this product.

On July 12, 2010, Stiefel Research Australia Pty. Ltd. filed suit alleging patent infringement in the United States District Court for the District of Delaware to prevent Perrigo from proceeding with the commercialization of this product. This action formally initiates the process under the Hatch-Waxman Act.  

The product is the AB-rated equivalent to Stiefel Laboratories' Olux® -E Foam, 0.05%, a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. Sales for the brand were up 18% year over year at approximately $41.5 million, according to Wolters Kluwer data for the twelve months ending May 2010.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing reflects our strategy to be first to market with the important products that make quality healthcare more affordable for our customers and drive value for our shareholders."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, infant formula, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Acquires Exclusive Sales and Distribution Rights to OTC Store Brand Versions of Allegra® and Allegra D-12 From Teva
2. Perrigo Company to Present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging and Leisure Conference
3. Perrigo Company to Present at the 31st Annual Goldman Sachs Global Healthcare Conference
4. Perrigo Announces FDA Final Approval for Miconazole
5. Perrigo Acquires Rights to Generic Version of HalfLytely® from Novel Laboratories
6. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Acquires Infant Formula Manufacturer PBM Holdings for $808 Million
9. Perrigo Company Announces Quarterly Dividend
10. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
11. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time ... already been receiving positive feedback from customers trying the product for the first time, ... Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at ...
(Date:9/20/2017)... ... ... The Centers for Medicare and Medicaid Services (CMS) stated in the Inpatient ... Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments over the next ... on October 17, 2017 at 2 P.M. EST and uncover how you can prepare ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... feel good program from Leany Greeny delivers positive results in just three weeks. ... health and kickstart the metabolism. Fitting seamlessly into hectic work and family schedules, ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting ... an average life. This mouse sets out on a journey that will show that ... is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Psalms of ... give peace of mind and move the readers one step closer to God. “Psalms ... has realized that his mistakes that have been made within his life are the ...
Breaking Medicine News(10 mins):